1. Home
  2. EXR vs INSM Comparison

EXR vs INSM Comparison

Compare EXR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extra Space Storage Inc

EXR

Extra Space Storage Inc

HOLD

Current Price

$144.36

Market Cap

30.3B

Sector

Real Estate

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$104.19

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXR
INSM
Founded
1977
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
30.1B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
EXR
INSM
Price
$144.36
$104.19
Analyst Decision
Buy
Strong Buy
Analyst Count
15
24
Target Price
$144.80
$201.17
AVG Volume (30 Days)
1.1M
2.4M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
4.61%
N/A
EPS Growth
13.90
N/A
EPS
1.14
N/A
Revenue
$3,377,542,000.00
N/A
Revenue This Year
N/A
$182.31
Revenue Next Year
$3.63
$65.19
P/E Ratio
$125.92
N/A
Revenue Growth
3.70
N/A
52 Week Low
$125.71
$64.85
52 Week High
$155.19
$212.75

Technical Indicators

Market Signals
Indicator
EXR
INSM
Relative Strength Index (RSI) 57.95 25.01
Support Level $136.49 N/A
Resistance Level $148.85 $166.81
Average True Range (ATR) 2.90 6.94
MACD 0.17 -3.85
Stochastic Oscillator 85.11 12.12

Price Performance

Historical Comparison
EXR
INSM

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: